Core B: Infectious Disease Assay Development

核心 B：传染病检测方法开发

• 批准号: 8812374
• 负责人: P Scott Hefty
• 金额: $ 21.17万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-15 至 2021-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8812374
• 关键词: Animal Model; Area; Attention; Biochemical; Biological; Biological Assay; Biology; Biomedical Research; Cells; Chemicals; Communicable Diseases; Communication; Communities; Containment; Core Facility; Development; Disease; Ensure; Funding Opportunities; Genetic; Goals; Individual; Kansas; Lead; Molecular Probes; Organism; Outcome; Pathogenesis; Performance; Pharmaceutical Chemistry; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Scientist; Services; Source; Therapeutic; Training; United States National Institutes of Health; Universities; Validation; Virulence Factors; assay development; base; design; experience; hazard; high throughput screening; microbial; response; screening; small molecule libraries

SUMMARY The overall goal of the Infectious Disease Assay Development (IDAD) Core is provide expertise, facilities, services, and training in the area of HTS assay design, development, validation, small and large-scale screening for organism (cell) based or biochemical infectious disease targets. Assay development and performing high-throughput screening for infectious disease targets can be very similar to other biological and disease targets; however, there are often specific biological hazards associated with infectious disease targets that can require special consideration and conditions. This core will build upon current assets and expand the current capabilities by providing enabling expertise and dedicated attention of a core director and a technician to the community of infectious disease scientists and their biologically and disease relevant targets. Core staff will facilitate design, development, validation of assays suitable for automated high-throughput chemical screening. They will also facilitate small or large scale screening of compounds (at KU or from external sources). The expected outcomes of this core and associated efforts are well developed and validated assays suitable for automated large-scale screening that can be performed internally or externally. Hits generated through successful assay development and limited or large scale screening efforts will be directed into Core C and Core D to identify lead compounds for use as molecular probes and pre-therapeutics for infectious diseases. The expertise and resources will also enable investigators to develop competitive proposals in response to NIH funding opportunities.

摘要 传染病检测开发(IDAD)核心的总体目标是提供专业知识、设施、 在HTS化验设计、开发、验证、小规模和大型领域的服务和培训 筛选以生物体(细胞)为基础的或生化传染病目标。化验发展和 对传染病目标执行高通量筛查可能非常类似于其他生物和 疾病目标；然而，往往有与传染病目标相关的特定生物危害。 这可能需要特殊的考虑和条件。这一核心将建立在现有资产的基础上，并扩展 通过提供支持专业知识和核心总监和技术人员的专心关注来实现当前的能力 传染病科学家和他们的生物学和疾病相关目标社区。核心员工 将促进适合自动化高通量化学品的分析的设计、开发和验证 放映。它们还将促进对化合物的小规模或大规模筛选(在KU或从外部 资料来源)。这一核心和相关工作的预期结果是经过良好开发和验证的分析 适用于可在内部或外部进行的自动化大规模筛查。生成的点击数 通过成功的化验开发和有限或大规模的筛查工作，将直接进入Core C 和核心D用于鉴定先导化合物，用作分子探针和感染的治疗前药物 疾病。专业知识和资源还将使调查人员能够在 回应美国国立卫生研究院的资助机会。